Additionally, MPN patients may be at risk for hypo-fibrinolysis, as one study demonstrated significantly elevated levels of plasminogen activator inhibitor type 1 (PAI-1), the inhibitor of tissue plasminogen activator (tPA), in the blood of MPN patients [25]. This evidence concerns the gene PLAT and myeloproliferative neoplasm.